Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Viridian Therapeutics stock

Own Viridian Therapeutics stock in just a few minutes.

Viridian Therapeutics, Inc is a biotechnology business based in the US. Viridian Therapeutics shares (MGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Viridian Therapeutics employs 45 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Viridian Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Viridian Therapeutics share price

Use our graph to track the performance of MGEN stocks over time.

Viridian Therapeutics shares at a glance

Information last updated 2021-03-10.
52-week range$4.67 - $25.67
50-day moving average $19.64
200-day moving average $16.00
Wall St. target price$31.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.29

Buy Viridian Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Viridian Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viridian Therapeutics financials

Revenue TTM $1.9 million
Gross profit TTM $-28,633,000
Return on assets TTM -48.09%
Return on equity TTM -136.12%
Profit margin 0%
Book value $5.53
Market capitalisation $89.9 million

TTM: trailing 12 months

Shorting Viridian Therapeutics shares

There are currently 133,760 Viridian Therapeutics shares held short by investors – that's known as Viridian Therapeutics's "short interest". This figure is 17.3% down from 161,699 last month.

There are a few different ways that this level of interest in shorting Viridian Therapeutics shares can be evaluated.

Viridian Therapeutics's "short interest ratio" (SIR)

Viridian Therapeutics's "short interest ratio" (SIR) is the quantity of Viridian Therapeutics shares currently shorted divided by the average quantity of Viridian Therapeutics shares traded daily (recently around 85743.58974359). Viridian Therapeutics's SIR currently stands at 1.56. In other words for every 100,000 Viridian Therapeutics shares traded daily on the market, roughly 1560 shares are currently held short.

However Viridian Therapeutics's short interest can also be evaluated against the total number of Viridian Therapeutics shares, or, against the total number of tradable Viridian Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viridian Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Viridian Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0458% of the tradable shares (for every 100,000 tradable Viridian Therapeutics shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Viridian Therapeutics.

Find out more about how you can short Viridian Therapeutics stock.

Viridian Therapeutics share dividends

We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.

Have Viridian Therapeutics's shares ever split?

Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.

Viridian Therapeutics share price volatility

Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $4.665 up to $25.67. A popular way to gauge a stock's volatility is its "beta".

MGEN.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 1.3214. This would suggest that Viridian Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viridian Therapeutics overview

Miragen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site